{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:49:54Z","timestamp":1790369394409,"version":"4.1.0"},"reference-count":121,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertension (HTN) is a common cardiovascular risk factor leading to heart failure (HF), coronary artery disease (CAD), stroke, peripheral artery disease and chronic renal failure. Hypertensive heart disease can manifest as many types of cardiac arrhythmias, most commonly being atrial fibrillation (AF). Both supraventricular and ventricular arrhythmias may occur in HTN patients, especially in those with left ventricular hypertrophy (LVH), CAD, or HF. In addition, high doses of thiazide diuretics commonly used to treat HTN, may result in electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia), contributing further to arrhythmias, while effective blood pressure control may prevent the development of the arrhythmias such as AF. In recognizing this close relationship between HTN and arrhythmias, the European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) Council on Hypertension convened a Task Force, with representation from the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE), with the remit of comprehensively reviewing the available evidence and publishing a joint consensus document on HTN and cardiac arrhythmias, and providing up-to-date consensus recommendations for use in clinical practice. The ultimate judgment on the care of a specific patient must be made by the healthcare provider and the patient in light of all individual factors presented. This is an executive summary of the full document co-published by EHRA in EP-Europace.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvx019","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T17:02:37Z","timestamp":1495558957000},"page":"235-250","source":"Crossref","is-referenced-by-count":46,"title":["Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE)"],"prefix":"10.1093","volume":"3","author":[{"given":"Gregory Y H","family":"Lip","sequence":"first","affiliation":[{"name":"1Institute of Cardiovascular Science, University of Birmingham, UK"},{"name":"2Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Coca","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Hypertension and Vascular Risk Unit, Hospital Cl\u00ednic (IDIBAPS), University of Barcelona, c\/Villarroel 170, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kahan","sequence":"additional","affiliation":[{"name":"4Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden"},{"name":"5Department of Cardiology, Danderyd University Hospital Corp, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"6Cardiology Department, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis S","family":"Manolis","sequence":"additional","affiliation":[{"name":"7Third Department of Cardiology, Athens University School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Hecht","family":"Olsen","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine, Holbaek Hospital and Centre for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, University of Southern Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Oto","sequence":"additional","affiliation":[{"name":"9Department of Cardiology, Memorial Ankara Hospital; Heart and Health Foundation of Turkey, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana S","family":"Potpara","sequence":"additional","affiliation":[{"name":"10School of Medicine, Cardiology Clinic, Belgrade University, Clinical Centre of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Steffel","sequence":"additional","affiliation":[{"name":"11Department of Cardiology, Electrophysiology and Cardiac Devices, University Heart Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[{"name":"12Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcio Jansen","family":"de Oliveira Figueiredo","sequence":"additional","affiliation":[{"name":"13Cardiology Department, Medicine School, State University of Campinas, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"de Simone","sequence":"additional","affiliation":[{"name":"14Department of Translational Medical Sciences, Federico II University Hospital, via S. Pansini 5, bld # 1, Napoli 80131, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy S","family":"Tzou","sequence":"additional","affiliation":[{"name":"15Division of Cardiology, Cardiac Electrophysiology, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chern","family":"En Chiang","sequence":"additional","affiliation":[{"name":"16Division of Cardiology, National Yang-Ming University, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[{"name":"17Institute of Cardiovascular Science, University College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Reviewers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe-Andrei","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Gorenek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Savelieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hatala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Brguljan-Hitij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Erdine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Lovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Salinas-Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"2026091105214331500_pvx019-B1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/jhh.2008.10","article-title":"Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications","volume":"22","author":"Yiu","year":"2008","journal-title":"J Hum Hypertens"},{"key":"2026091105214331500_pvx019-B2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ajh.2012.75","article-title":"Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension","volume":"25","author":"Eguchi","year":"2012","journal-title":"Am J Hypertens"},{"key":"2026091105214331500_pvx019-B3","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/europace\/euw161","article-title":"EHRA\/HRS\/APHRS\/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterization, and clinical implication","volume":"18","author":"Goette","year":"2016","journal-title":"Europace"},{"key":"2026091105214331500_pvx019-B4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.33549\/physiolres.931101","article-title":"Adaptation of the heart to hypertension is associated with maladaptive gap junction connexin-43 remodeling","volume":"57","author":"Fialova","year":"2008","journal-title":"Physiol Res"},{"key":"2026091105214331500_pvx019-B5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/eurheartj\/ehp046","article-title":"Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles","volume":"30","author":"Goette","year":"2009","journal-title":"Eur Heart J"},{"key":"2026091105214331500_pvx019-B6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/jce.12578","article-title":"A prospective DE-MRI study evaluating the role of TGF-beta1 in left atrial fibrosis and implications for outcomes of cryoballoon-based catheter ablation: new insights into primary fibrotic atriocardiomyopathy","volume":"26","author":"Canpolat","year":"2015","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026091105214331500_pvx019-B7","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.jacc.2015.03.557","article-title":"Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences","volume":"65","author":"Hirsh","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/eurheartj\/ehw119","article-title":"Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation","volume":"38","author":"Spronk","year":"2017","journal-title":"Eur Heart J"},{"key":"2026091105214331500_pvx019-B9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/CIRCRESAHA.116.304679","article-title":"Cardiac innervation and sudden cardiac death","volume":"116","author":"Fukuda","year":"2015","journal-title":"Circ Res"},{"key":"2026091105214331500_pvx019-B10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/anec.12003","article-title":"Electrocardiographic predictors of sudden cardiac death in patients with left ventricular hypertrophy","volume":"18","author":"Panikkath","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"2026091105214331500_pvx019-B11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/hrt.2004.042473","article-title":"Left ventricular hypertrophy in hypertension: its arrhythmogenic potential","volume":"91","author":"Kahan","year":"2005","journal-title":"Heart"},{"key":"2026091105214331500_pvx019-B12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11906-001-0040-8","article-title":"Are sleep-related breathing disorders important contributing factors to the production of essential hypertension?","volume":"3","author":"Silverberg","year":"2001","journal-title":"Curr Hypertens Rep"},{"key":"2026091105214331500_pvx019-B13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1524-6175.2001.00491.x","article-title":"Obstructive sleep apnea and hypertension: from correlative to causative relationship","volume":"3","author":"Lavie","year":"2001","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026091105214331500_pvx019-B14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(84)91107-3","article-title":"Sleep apnoea in a hypertensive population","volume":"2","author":"Kales","year":"1984","journal-title":"Lancet"},{"key":"2026091105214331500_pvx019-B15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1113\/eph8702336","article-title":"Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart","volume":"87","author":"Tribulova","year":"2002","journal-title":"Exp Physiol"},{"key":"2026091105214331500_pvx019-B16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pcad.2008.01.003","article-title":"The role of the autonomic nervous system in sudden cardiac death","volume":"50","author":"Vaseghi","year":"2008","journal-title":"Prog Cardiovasc Dis"},{"key":"2026091105214331500_pvx019-B17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0895-7061(97)00127-1","article-title":"Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease","volume":"10","author":"Novo","year":"1997","journal-title":"Am J Hypertens"},{"key":"2026091105214331500_pvx019-B18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1253\/jcj.64.499","article-title":"Cardiac arrhythmias and left ventricular hypertrophy in dipper and nondipper patients with essential hypertension","volume":"64","author":"Ijiri","year":"2000","journal-title":"Jpn Circ J"},{"key":"2026091105214331500_pvx019-B19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/hrt.2005.069542","article-title":"Atrial extrasystoles after exercise predict atrial fibrillation in patients with left ventricular hypertrophy","volume":"92","author":"Folkeringa","year":"2006","journal-title":"Heart"},{"key":"2026091105214331500_pvx019-B20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jacc.2015.05.018","article-title":"Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation","volume":"66","author":"Larsen","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B21","doi-asserted-by":"crossref","first-page":"e002519.","DOI":"10.1161\/JAHA.112.002519","article-title":"Premature cardiac contractions and risk of incident ischemic stroke","volume":"1","author":"Ofoma","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"2026091105214331500_pvx019-B22","doi-asserted-by":"crossref","first-page":"2n","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"2026091105214331500_pvx019-B23","first-page":"e63479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry","volume-title":"PLoS One","author":"Kakkar","year":"2013"},{"key":"2026091105214331500_pvx019-B24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"key":"2026091105214331500_pvx019-B25","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2026091105214331500_pvx019-B26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/HYPERTENSIONAHA.111.179713","article-title":"Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study","volume":"59","author":"Grundvold","year":"2012","journal-title":"Hypertension"},{"key":"2026091105214331500_pvx019-B27","doi-asserted-by":"crossref","first-page":"e000102.","DOI":"10.1161\/JAHA.112.000102","article-title":"Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium","volume":"2","author":"Alonso","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026091105214331500_pvx019-B28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1378\/chest.11-0340","article-title":"A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study","volume":"141","author":"Potpara","year":"2012","journal-title":"Chest"},{"key":"2026091105214331500_pvx019-B29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2026091105214331500_pvx019-B30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2026091105214331500_pvx019-B31","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"2026091105214331500_pvx019-B32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"2026091105214331500_pvx019-B33","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1016\/j.ijcard.2013.07.234","article-title":"A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study","volume":"168","author":"Potpara","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026091105214331500_pvx019-B34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.amjcard.2014.07.015","article-title":"Meta-analysis of left ventricular hypertrophy and sustained arrhythmias","volume":"114","author":"Chatterjee","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026091105214331500_pvx019-B35","first-page":"S42","article-title":"Combining other antihypertensive drugs with beta-blockers in hypertension: a focus on safety and tolerability","volume":"30","author":"Richards","year":"2014","journal-title":"Can J Cardiol"},{"key":"2026091105214331500_pvx019-B36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.885","article-title":"Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting","volume":"12","author":"Almenoff","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026091105214331500_pvx019-B37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM198608143150704","article-title":"Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial","volume":"315","author":"Gibson","year":"1986","journal-title":"N Engl J Med"},{"key":"2026091105214331500_pvx019-B38","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","author":"Group KDIGOKBPW","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2026091105214331500_pvx019-B39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1753944710381603","article-title":"Evaluation of left ventricular hypertrophy in patients requiring permanent pacing","volume":"4","author":"Alexopoulos","year":"2010","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026091105214331500_pvx019-B40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/eurheartj\/ehl436","article-title":"Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study","volume":"28","author":"Rienstra","year":"2007","journal-title":"Eur Heart J"},{"key":"2026091105214331500_pvx019-B41","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jacc.2008.05.002","article-title":"Sleep apnea and cardiovascular disease: an American Heart Association\/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing","volume":"52","author":"Somers","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jelectrocard.2010.09.012","article-title":"Assessment of atrial conduction time in patients with essential hypertension","volume":"44","author":"Emiroglu","year":"2011","journal-title":"J Electrocardiol"},{"key":"2026091105214331500_pvx019-B43","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/HJH.0b013e3282fcc23c","article-title":"Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension study","volume":"26","author":"Li","year":"2008","journal-title":"J Hypertens"},{"key":"2026091105214331500_pvx019-B44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjmed.2014.09.016","article-title":"Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease","volume":"128","author":"Bohm","year":"2015","journal-title":"Am J Med"},{"key":"2026091105214331500_pvx019-B45","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/eurheartj\/ehn123","article-title":"Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR\/trandolapril STudy (INVEST)","volume":"29","author":"Kolloch","year":"2008","journal-title":"Eur Heart J"},{"key":"2026091105214331500_pvx019-B46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.acvd.2013.11.003","article-title":"Significance, prognostic value and management of heart rate in hypertension","volume":"107","author":"Courand","year":"2014","journal-title":"Archiv Cardiovasc Dis"},{"key":"2026091105214331500_pvx019-B47","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(16)31258-2","article-title":"Rate control in atrial fibrillation","volume":"388","author":"Van Gelder","year":"2016","journal-title":"Lancet"},{"key":"2026091105214331500_pvx019-B48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jchf.2012.09.002","article-title":"Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis","volume":"1","author":"Rienstra","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026091105214331500_pvx019-B49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.amjcard.2009.04.040","article-title":"Meta-analysis of ablation of atrial flutter and supraventricular tachycardia","volume":"104","author":"Spector","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026091105214331500_pvx019-B50","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.109.874982","article-title":"Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke","volume":"121","author":"Binici","year":"2010","journal-title":"Circulation"},{"key":"2026091105214331500_pvx019-B51","first-page":"e1","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO)","volume":"50","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"2026091105214331500_pvx019-B52","first-page":"1","article-title":"Diving to the foot of an iceberg: the SEARCH for undiagnosed atrial fibrillation","volume":"112","author":"Potpara","year":"2014","journal-title":"Thromb Haemost"},{"key":"2026091105214331500_pvx019-B53","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jacc.2015.06.488","article-title":"Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT Study","volume":"66","author":"Pathak","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B54","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1160\/TH14-03-0231","article-title":"Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study","volume":"111","author":"Lowres","year":"2014","journal-title":"Thromb Haemost"},{"key":"2026091105214331500_pvx019-B55","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"2026091105214331500_pvx019-B56","article-title":"European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular rrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci\u00f3n Cardiaca y Electrofisiologia (SOLAECE)","author":"Katritsis","year":"2016","journal-title":"Europace"},{"key":"2026091105214331500_pvx019-B57","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jacc.2003.08.013","article-title":"ACC\/AHA\/ESC guidelines for the management of patients with supraventricular arrhythmias\u2014executive summary: a report of the American college of cardiology\/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) Developed in Collaboration with NASPE-Heart Rhythm Society","volume":"42","author":"Blomstr\u00f6m-Lundqvist","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B58","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jacc.2015.08.856","article-title":"2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"67","author":"Page","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11208210-000000000-00000","article-title":"Esmolol","volume":"72","author":"Garnock-Jones","year":"2012","journal-title":"Drugs"},{"key":"2026091105214331500_pvx019-B60","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euw064","article-title":"Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial","author":"Katritsis","year":"2016","journal-title":"Europace"},{"key":"2026091105214331500_pvx019-B61","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"2026091105214331500_pvx019-B62","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","author":"Freedman","year":"2016","journal-title":"Lancet"},{"key":"2026091105214331500_pvx019-B63","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1160\/TH15-07-0565","article-title":"Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy","volume":"114","author":"Lip","year":"2015","journal-title":"Thromb Haemost"},{"key":"2026091105214331500_pvx019-B64","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/STROKEAHA.110.580506","article-title":"Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study","volume":"41","author":"Toyoda","year":"2010","journal-title":"Stroke"},{"key":"2026091105214331500_pvx019-B65","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-vitamin K antagonist oral anticoagulants for stroke prevention in asian patients with nonvalvular atrial fibrillation: meta-analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"key":"2026091105214331500_pvx019-B66","doi-asserted-by":"crossref","first-page":"e002015","DOI":"10.1161\/JAHA.115.002015","article-title":"Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"4","author":"Rao","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2026091105214331500_pvx019-B67","doi-asserted-by":"crossref","first-page":"e004549.","DOI":"10.1161\/JAHA.112.004549","article-title":"Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis","volume":"2","author":"Ganesan","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026091105214331500_pvx019-B68","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.300.15.1784","article-title":"Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial","volume":"300","author":"Ahmed","year":"2008","journal-title":"JAMA"},{"key":"2026091105214331500_pvx019-B69","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/jth.13386","article-title":"Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores","volume":"14","author":"Lip","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2026091105214331500_pvx019-B70","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/eurheartj\/ehq079","article-title":"Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation","volume":"31","author":"Nault","year":"2010","journal-title":"Eur Heart J"},{"key":"2026091105214331500_pvx019-B71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(16)31277-6","article-title":"Rhythm control in atrial fibrillation","volume":"388","author":"Piccini","year":"2016","journal-title":"Lancet"},{"key":"2026091105214331500_pvx019-B72","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM198709243171302","article-title":"Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy","volume":"317","author":"McLenachan","year":"1987","journal-title":"N Engl J Med"},{"key":"2026091105214331500_pvx019-B73","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/eurheartj\/14.11.1548","article-title":"High blood pressure and ventricular arrhythmias","volume":"14","author":"Sideris","year":"1993","journal-title":"Eur Heart J"},{"key":"2026091105214331500_pvx019-B74","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/0002-9149(87)90305-5","article-title":"Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study","volume":"60","author":"Levy","year":"1987","journal-title":"Am J Cardiol"},{"key":"2026091105214331500_pvx019-B75","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/europace\/euu362","article-title":"Ventricular arrhythmias in aortic valve stenosis before and after transcatheter aortic valve implantation","volume":"17","author":"Tempio","year":"2015","journal-title":"Europace"},{"key":"2026091105214331500_pvx019-B76","doi-asserted-by":"crossref","first-page":"141B","DOI":"10.1016\/S0735-1097(85)80545-3","article-title":"Sudden death: Lessons from subsets in population studies","volume":"5","author":"Kannel","year":"1985","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B77","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0735-1097(98)00407-0","article-title":"Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death","volume":"32","author":"Haider","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B78","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0895-7061(98)00036-3","article-title":"Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity","volume":"11","author":"Manolis","year":"1998","journal-title":"Am J Hypertens"},{"key":"2026091105214331500_pvx019-B79","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0895-7061(01)01297-3","article-title":"Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH","volume":"14","author":"Novo","year":"2001","journal-title":"Am J Hypertens"},{"key":"2026091105214331500_pvx019-B80","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jama.1992.03480080053026","article-title":"Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men","volume":"267","author":"Siegel","year":"1992","journal-title":"JAMA"},{"key":"2026091105214331500_pvx019-B81","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.666594","article-title":"Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death. The LIFE Study","volume":"116","author":"Wachtell","year":"2007","journal-title":"Circulation"},{"key":"2026091105214331500_pvx019-B82","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1056\/NEJM199406303302603","article-title":"Diuretic therapy for hypertension and the risk of primary cardiac arrest","volume":"330","author":"Siscovick","year":"1994","journal-title":"N Engl J Med"},{"key":"2026091105214331500_pvx019-B83","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1472-8206.2010.00835.x","article-title":"Mechanisms of hypokalemia-induced ventricular arrhythmogenicity","volume":"24","author":"Osadchil","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"2026091105214331500_pvx019-B84","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","article-title":"Effects of Candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial","volume":"51","author":"Ogihara","year":"2008","journal-title":"Hypertension"},{"key":"2026091105214331500_pvx019-B85","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(03)14183-9","article-title":"Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study","volume":"362","author":"Lindholm","year":"2003","journal-title":"Lancet"},{"key":"2026091105214331500_pvx019-B86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"2026091105214331500_pvx019-B87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCEP.111.963348","article-title":"Premature ventricular contraction-induced cardiomyopathy: a treatable condition","volume":"5","author":"Lee","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026091105214331500_pvx019-B88","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.jhh.1000908","article-title":"QTc dispersion and complex ventricular arrhythmias in untreated newly presenting hypertensive patients","volume":"13","author":"Saadeh","year":"1999","journal-title":"J Hum Hypertens"},{"key":"2026091105214331500_pvx019-B89","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/0002-9149(92)90792-W","article-title":"Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy","volume":"69","author":"Pringle","year":"1992","journal-title":"Am J Cardiol"},{"key":"2026091105214331500_pvx019-B90","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2026091105214331500_pvx019-B91","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","article-title":"Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies","volume":"54","author":"Fagard","year":"2009","journal-title":"Hypertension"},{"key":"2026091105214331500_pvx019-B92","doi-asserted-by":"crossref","first-page":"b1665.","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"2026091105214331500_pvx019-B93","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.hrthm.2009.04.030","article-title":"EHRA\/HRS expert consensus on catheter ablation of ventricular arrhythmias","volume":"6","author":"Aliot","year":"2009","journal-title":"Heart Rhythm"},{"key":"2026091105214331500_pvx019-B94","first-page":"1","article-title":"Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy","volume":"0","author":"El Kadri","year":"2015","journal-title":"Heart Rhythm"},{"key":"2026091105214331500_pvx019-B95","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.02.032","article-title":"ACC\/AHA\/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the ACC\/AHA\/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons","volume":"51","author":"Epstein","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B96","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"key":"2026091105214331500_pvx019-B97","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijcard.2015.07.019","article-title":"Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network","volume":"199","author":"Losi","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026091105214331500_pvx019-B98","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","article-title":"Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study","volume":"128","author":"Zakeri","year":"2013","journal-title":"Circulation"},{"key":"2026091105214331500_pvx019-B99","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jacc.2015.06.1084","article-title":"Orthostatic hypotension: epidemiology, prognosis, and treatment","volume":"66","author":"Ricci","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B100","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/HYPERTENSIONAHA.115.05913","article-title":"Cardiac organ damage and arterial stiffness in autonomic failure: comparison with essential hypertension","volume":"66","author":"Milazzo","year":"2015","journal-title":"Hypertension"},{"key":"2026091105214331500_pvx019-B101","doi-asserted-by":"crossref","first-page":"e0146156.","DOI":"10.1371\/journal.pone.0146156","article-title":"Single agent antihypertensive therapy and orthostatic blood pressure behaviour in older adults using beat-to-beat measurements: the Irish longitudinal study on ageing","volume":"11","author":"Canney","year":"2016","journal-title":"PloS one"},{"key":"2026091105214331500_pvx019-B102","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1160\/TH07-08-0508","article-title":"Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data","volume":"99","author":"Hughes","year":"2008","journal-title":"Thromb Haemost"},{"key":"2026091105214331500_pvx019-B103","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026091105214331500_pvx019-B104","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1474-4422(13)70049-8","article-title":"Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies","volume":"12","author":"Lauer","year":"2013","journal-title":"Lancet Neurol"},{"key":"2026091105214331500_pvx019-B105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/qjmed\/hcm076","article-title":"Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review","volume":"100","author":"Hughes","year":"2007","journal-title":"QJM"},{"key":"2026091105214331500_pvx019-B106","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/eurheartj\/ehl504","article-title":"Effect of hypertension on anticoagulated patients with atrial fibrillation","volume":"28","author":"Lip","year":"2007","journal-title":"Eur Heart J"},{"key":"2026091105214331500_pvx019-B107","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026091105214331500_pvx019-B108","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026091105214331500_pvx019-B109","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026091105214331500_pvx019-B110","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/CIRCULATIONAHA.114.008643","article-title":"Outcomes registry for better informed treatment of atrial fibrillation I and patients. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"129","author":"Steinberg","year":"2014","journal-title":"Circulation"},{"key":"2026091105214331500_pvx019-B111","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH11-05-0364","article-title":"Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a \u2032real world\u2032 nationwide cohort study","volume":"106","author":"Olesen","year":"2011","journal-title":"Thromb Haemost"},{"key":"2026091105214331500_pvx019-B112","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026091105214331500_pvx019-B113","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/STROKEAHA.116.013253","article-title":"Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?","volume":"47","author":"Fauchier","year":"2016","journal-title":"Stroke"},{"key":"2026091105214331500_pvx019-B114","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026091105214331500_pvx019-B115","first-page":"465","article-title":"Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation","volume":"111","author":"Lahaye","year":"2014","journal-title":"Thromb Haemost"},{"key":"2026091105214331500_pvx019-B116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-6175.2003.02463.x","article-title":"The economic impact of hypertension","volume":"5(3 Suppl 2)","author":"Elliott","year":"2003","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026091105214331500_pvx019-B117","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/eurheartj\/eht031","article-title":"Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association","volume":"34","author":"Boriani","year":"2013","journal-title":"Eur Heart J"},{"key":"2026091105214331500_pvx019-B118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1524-4733.2006.00160.x","article-title":"The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study","volume":"10","author":"Bruggenjurgen","year":"2007","journal-title":"Value Health"},{"key":"2026091105214331500_pvx019-B119","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.08.022","article-title":"Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France","volume":"23","author":"Cotte","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2026091105214331500_pvx019-B120","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40273-013-0090-1","article-title":"Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants","volume":"31","author":"Kasmeridis","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"2026091105214331500_pvx019-B121","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/eurheartj\/ehu006","article-title":"Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation","volume":"35","author":"Dorian","year":"2014","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal \u2013 Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/3\/4\/235\/70577448\/ehjcvp_3_4_235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/3\/4\/235\/70577448\/ehjcvp_3_4_235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:22:03Z","timestamp":1789118523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/3\/4\/235\/3854665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":121,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,6,20]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvx019","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,6,20]]}}}